Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Prestige Consumer Healthcare Inc.    PBH

PRESTIGE CONSUMER HEALTHCARE INC.

(PBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The group's high margin levels account for strong profits.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Its low valuation, with P/E ratio at 11.7 and 11.41 for the ongoing fiscal year and 2022 respectively, makes the stock pretty attractive with regard to earnings multiples.
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
PRESTIGE CONSUMER HEALTHCAR..8.35%1 893
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271
ABBVIE INC.4.18%197 080
ELI LILLY AND COMPANY10.57%169 250
NOVO NORDISK A/S2.48%165 077
BRISTOL-MYERS SQUIBB COMPAN..6.43%149 189
AMGEN INC.5.11%140 687
ASTRAZENECA PLC3.21%135 863
SANOFI2.88%123 562
GLAXOSMITHKLINE PLC3.83%95 210
CHUGAI PHARMACEUTICAL CO., ..7.11%91 993
JIANGSU HENGRUI MEDICINE CO..-1.46%90 348
More Results
Financials (USD)
Sales 2021 927 M - -
Net income 2021 164 M - -
Net Debt 2021 - - -
P/E ratio 2021 11,7x
Yield 2021 -
Capitalization 1 893 M 1 893 M -
Capi. / Sales 2021 2,04x
Capi. / Sales 2022 2,01x
Nbr of Employees 520
Free-Float 92,2%
Upcoming event on PRESTIGE CONSUMER HEALTHCARE INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes